Tenax Therapeutics, Inc.
Organization
Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing novel cardiopulmonary therapies. The company's primary development programs target pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).
What experts have said about Tenax Therapeutics, Inc.
2 statements · 2 negative
Tenax Therapeutics shares fell more than 90% in one day.
“the shares plummeted over 90% today.”
Open the episode · Berkshire Jumps, Monday.com Falls, Tenax PlummetsListen at 3:39
Tenax Therapeutics has about $50 million market capitalization after erasing roughly $450 million.
“It's Only now about $50 million in market cap but of course it had erased about 450 million.”
Open the episode · Berkshire Jumps, Monday.com Falls, Tenax PlummetsListen at 4:18
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
